Phase 3 and Extensional Study of Besifovir

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2013
To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic hepatitis B patients
Epistemonikos ID: 106aca5ed448cd33c602a25bc93b2917cf71e9a2
First added on: Nov 24, 2021